Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ARS Pharmaceuticals (SPRY) Total Debt: 2021

Historic Total Debt for ARS Pharmaceuticals (SPRY) over the last 1 years, with Dec 2021 value amounting to $4.9 million.

  • ARS Pharmaceuticals' Total Debt was N/A to $4.9 million in Q4 2021 from the same period last year, while for Dec 2021 it was $4.9 million, marking a year-over-year change of. This contributed to the annual value of $4.9 million for FY2021, which is N/A change from last year.
  • Latest data reveals that ARS Pharmaceuticals reported Total Debt of $4.9 million as of FY2021.
  • ARS Pharmaceuticals' Total Debt's 5-year high stood at $4.9 million during FY2021, with a 5-year trough of $4.9 million in FY2021.
  • In the last 1 years, ARS Pharmaceuticals' Total Debt had a median value of $4.9 million in 2021 and averaged $4.9 million.